These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
424 related articles for article (PubMed ID: 27693630)
1. Acetyl-CoA carboxylase rewires cancer metabolism to allow cancer cells to survive inhibition of the Warburg effect by cetuximab. Luo J; Hong Y; Lu Y; Qiu S; Chaganty BK; Zhang L; Wang X; Li Q; Fan Z Cancer Lett; 2017 Jan; 384():39-49. PubMed ID: 27693630 [TBL] [Abstract][Full Text] [Related]
2. AMPK-mediated energy homeostasis and associated metabolic effects on cancer cell response and resistance to cetuximab. Li X; Lu Y; Lu H; Luo J; Hong Y; Fan Z Oncotarget; 2015 May; 6(13):11507-18. PubMed ID: 25871473 [TBL] [Abstract][Full Text] [Related]
3. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma. Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738 [TBL] [Abstract][Full Text] [Related]
4. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis. Lu H; Li X; Lu Y; Qiu S; Fan Z Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723 [TBL] [Abstract][Full Text] [Related]
5. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models. Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485 [TBL] [Abstract][Full Text] [Related]
6. CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab. Niehr F; Weichert W; Stenzinger A; Budach V; Tinhofer I J Transl Med; 2015 Apr; 13():106. PubMed ID: 25890004 [TBL] [Abstract][Full Text] [Related]
7. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors. Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323 [TBL] [Abstract][Full Text] [Related]
8. Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K Braig F; Kriegs M; Voigtlaender M; Habel B; Grob T; Biskup K; Blanchard V; Sack M; Thalhammer A; Ben Batalla I; Braren I; Laban S; Danielczyk A; Goletz S; Jakubowicz E; Märkl B; Trepel M; Knecht R; Riecken K; Fehse B; Loges S; Bokemeyer C; Binder M Cancer Res; 2017 Mar; 77(5):1188-1199. PubMed ID: 28031227 [TBL] [Abstract][Full Text] [Related]
9. Hypoxia Mediates Differential Response to Anti-EGFR Therapy in HNSCC Cells. Wiechec E; Hansson KT; Alexandersson L; Jönsson JI; Roberg K Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468237 [TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor inhibition reduces angiogenesis via hypoxia-inducible factor-1α and Notch1 in head neck squamous cell carcinoma. Wang WM; Zhao ZL; Ma SR; Yu GT; Liu B; Zhang L; Zhang WF; Kulkarni AB; Sun ZJ; Zhao YF PLoS One; 2015; 10(2):e0119723. PubMed ID: 25723392 [TBL] [Abstract][Full Text] [Related]
11. AXL mediates resistance to cetuximab therapy. Brand TM; Iida M; Stein AP; Corrigan KL; Braverman CM; Luthar N; Toulany M; Gill PS; Salgia R; Kimple RJ; Wheeler DL Cancer Res; 2014 Sep; 74(18):5152-64. PubMed ID: 25136066 [TBL] [Abstract][Full Text] [Related]
12. The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models. D'Amato V; Rosa R; D'Amato C; Formisano L; Marciano R; Nappi L; Raimondo L; Di Mauro C; Servetto A; Fusciello C; Veneziani BM; De Placido S; Bianco R Br J Cancer; 2014 Jun; 110(12):2887-95. PubMed ID: 24823695 [TBL] [Abstract][Full Text] [Related]
13. Cetuximab reverses the Warburg effect by inhibiting HIF-1-regulated LDH-A. Lu H; Li X; Luo Z; Liu J; Fan Z Mol Cancer Ther; 2013 Oct; 12(10):2187-99. PubMed ID: 23920275 [TBL] [Abstract][Full Text] [Related]
14. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer. Keysar SB; Le PN; Anderson RT; Morton JJ; Bowles DW; Paylor JJ; Vogler BW; Thorburn J; Fernandez P; Glogowska MJ; Takimoto SM; Sehrt DB; Gan GN; Eagles-Soukup JR; Serracino H; Hirsch FR; Lucia MS; Thorburn A; Song JI; Wang XJ; Jimeno A Cancer Res; 2013 Jun; 73(11):3381-92. PubMed ID: 23576557 [TBL] [Abstract][Full Text] [Related]
15. Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress. Lin YC; Wu MH; Wei TT; Lin YC; Huang WC; Huang LY; Lin YT; Chen CC Oncotarget; 2014 Jan; 5(1):298-308. PubMed ID: 24457597 [TBL] [Abstract][Full Text] [Related]
16. Overcoming cetuximab resistance in HNSCC: the role of AURKB and DUSP proteins. Boeckx C; Op de Beeck K; Wouters A; Deschoolmeester V; Limame R; Zwaenepoel K; Specenier P; Pauwels P; Vermorken JB; Peeters M; Van Camp G; Baay M; Lardon F Cancer Lett; 2014 Nov; 354(2):365-77. PubMed ID: 25192874 [TBL] [Abstract][Full Text] [Related]
17. Rational combination with PDK1 inhibition overcomes cetuximab resistance in head and neck squamous cell carcinoma. Lu H; Lu Y; Xie Y; Qiu S; Li X; Fan Z JCI Insight; 2019 Oct; 4(19):. PubMed ID: 31578313 [TBL] [Abstract][Full Text] [Related]
18. FGF21 does not require adipocyte AMP-activated protein kinase (AMPK) or the phosphorylation of acetyl-CoA carboxylase (ACC) to mediate improvements in whole-body glucose homeostasis. Mottillo EP; Desjardins EM; Fritzen AM; Zou VZ; Crane JD; Yabut JM; Kiens B; Erion DM; Lanba A; Granneman JG; Talukdar S; Steinberg GR Mol Metab; 2017 Jun; 6(6):471-481. PubMed ID: 28580278 [TBL] [Abstract][Full Text] [Related]
19. Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc. Jedlinski A; Garvin S; Johansson AC; Edqvist PH; Ponten F; Roberg K J Oral Pathol Med; 2017 Oct; 46(9):717-724. PubMed ID: 28036101 [TBL] [Abstract][Full Text] [Related]
20. mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations. Wang Z; Martin D; Molinolo AA; Patel V; Iglesias-Bartolome R; Degese MS; Vitale-Cross L; Chen Q; Gutkind JS J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25099740 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]